Press Release

Printer Friendly Version View printer-friendly version
<< Back
POZEN to Present at the RBC Capital Markets 2007 Healthcare Conference

CHAPEL HILL, N.C.--(BUSINESS WIRE)--Nov. 28, 2007--POZEN Inc. (NASDAQ: POZN) announced today that John R. Plachetka, Pharm.D., the company's chairman, president and chief executive officer, will participate in the "Deliver Us From Pain" panel discussion at the RBC Capital Markets 2007 Healthcare Conference on Wednesday, December 12, 2007 at 11:00 a.m. (ET) at the Westin Times Square Hotel in New York City. The event will be webcast and archived on POZEN's home page at www.pozen.com.

POZEN is a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs where it can improve efficacy, safety, and/or patient convenience. POZEN's efforts are focused primarily on the development of pharmaceutical products for the treatment of acute and chronic pain and other pain-related conditions. POZEN has development and commercialization alliances with GlaxoSmithKline for the proposed product candidate Trexima(TM) for the acute treatment of migraine, which is currently under review by the United States Food and Drug Administration, and with AstraZeneca for the proposed product candidate PN 400 for conditions such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing NSAID-associated gastric ulcers. The company's common stock is traded on The Nasdaq Stock Market under the symbol "POZN". For detailed company information, including copies of this and other press releases, see POZEN's website: www.pozen.com.

CONTACT: POZEN Inc.
Bill Hodges, 919-913-1030
Chief Financial Officer
or
Fran Barsky, 919-913-1044
Director, Investor Relations

SOURCE: POZEN Inc.


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.